Arjun V. Balar, MD, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.
Arjun V. Balar, MD, assistant professor in the Department of Medicine and director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.
According to Balar, CTLA-4 blockade is being tested in combination with PD-1 blockade. The PD-1 pathway can play an important role in the treatment of bladder cancer, but it still needs to be tested further. This strategy is being investigated in both the CheckMate901 trial and the DANUBE trial.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More